Advertisement
Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and development charge of approximately $24 million on a pre-tax basis.
This charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements.
This charge is expected to negatively impact each of GAAP and non-GAAP net income per share for the second quarter 2024 by approximately $0.18.
read more
Regeneron Pharma Q2 Results Top Estimates - Update
Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews
|
Pred 437 dňami
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews
|
Pred 471 dňami
Regeneron Pharma Q4 Results Top Estimates - Update
Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews
|
Pred 618 dňami
Regeneron Completes Acquiring Sanofi's Stake In Libtayo
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews
|
Pred 1199 dňami
U.S. Dollar Drops Against Majors
The U.S. dollar fell against its major counterparts in the New York session on Friday.
RTTNews
|
Pred 1 dňom
U.S. Govt Has Started To Fire Federal Workers
The U.S. government has started to layoff federal employees, the Office of Management and Budget's chief Russell Vought said on the 10th day of the shutdown. In a post on the social media platform X, Vought said, "The RIFs have begun." RIF is an acronym for reduction in force.
RTTNews
|
Pred 1 dňom
SMI Sheds Over 1% As Stocks Tumble In Final Hour
After moving along the flat line till the penultimate hour of the day's trading session on Friday, Switzerland's benchmark index SMI tumbled in the final hour, as trade tensions intensified after U.S. President Donald Trump threatened to impose massive tariffs on Chinese imports.
RTTNews
|
Pred 1 dňom
European Stocks Tumble As Trump Threatens Massive Tariffs On Chinese Imports
European stocks fell sharply on Friday as trade tensions intensified after U.S. President Donald Trump threatened that he will raise tariffs on Chinese imports, following China's decision to expand export controls on rare earth metals.
RTTNews
|
Pred 1 dňom
